Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.

@article{Baron2006FactorsAW,
  title={Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation.},
  author={F. Baron and R. Storb and B. Storer and M. Maris and D. Niederwieser and J. Shizuru and T. Chauncey and B. Bruno and S. Forman and P. Mcsweeney and R. Maziarz and M. Pulsipher and E. Agura and J. Wade and M. Sorror and D. Maloney and B. Sandmaier},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2006},
  volume={24 25},
  pages={
          4150-7
        }
}
  • F. Baron, R. Storb, +14 authors B. Sandmaier
  • Published 2006
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Several studies have investigated the feasibility of allogeneic hematopoietic cell transplantations (HCTs) after reduced-intensity conditioning in patients who experienced relapse after myeloablative HCT. Although most studies showed relatively low nonrelapse mortality (NRM) rates and encouraging short-term results, it has yet to be defined which patients would benefit most from these approaches. PATIENTS AND METHODS We analyzed data from 147 patients with hematologic malignancies who… Expand
Salvage allogeneic hematopoietic cell transplantation with fludarabine and low-dose total body irradiation after rejection of first allografts.
  • B. Gyurkocza, T. Cao, +9 authors B. Sandmaier
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2009
TLDR
It is concluded that graft rejection after allogeneic HCT could be overcome by salvage transplantation using conditioning with Flu and low-dose TBI and TBI dose did not have an impact on outcomes. Expand
Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.
  • C. Freytes, Mei-Jie Zhang, +22 authors P. Hari
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2012
TLDR
A quantitative risk model based on pretransplantation risk factors is described to identify those patients likely to benefit from this approach and correlated with improved PFS. Expand
Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen.
  • D. Maruyama, T. Fukuda, +11 authors Y. Takaue
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2007
TLDR
It is suggested that the antileukemia/lymphoma effect associated with RIST is comparable to that associated with CST and appears to be feasible for the treatment of hematologic malignancies not in remission. Expand
Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning
TLDR
It is concluded that acute GVHD, age, donor type, and conditioning intensity might have a role in the physiopathology of TMA after allogeneic HCT. Expand
Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313.
TLDR
Favorable outcomes can be achieved with RIC approaches in pediatric patients in remission who are ineligible for myeloablative transplantation. Expand
Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.
TLDR
The use of UCB after a nonmyeloablative conditioning as a strategy for extending the availability of transplantation therapy, particularly for older patients, is supported. Expand
Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Analysis in the Rituximab Era
TLDR
Encouraging results are reported with allo-HSCT for patients with rel/ref MCL, and high alemtuzumab doses should probably be avoided in this context. Expand
Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning.
  • S. Servais, F. Baron, Y. Beguin
  • Medicine
  • Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • 2011
Allogeneic hematopoietic stem cell transplantation (HSCT) following myeloablative (conventional) conditioning regimen is associated with a high incidence of transplant-related morbidity andExpand
Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant.
TLDR
This series suggests that SCT2 is feasible in patients relapsing after prior HCT1, with a lower treatment-related mortality than that reported for allogeneic transplant in this setting. Expand
Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.
  • F. Baron, B. Sandmaier, +15 authors R. Storb
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2007
TLDR
It is concluded that postgrafting immunosuppression with extended MMF and shortened CSP failed to decrease the incidence of GVHD among unrelated PBSC recipients given nonmyeloablative conditioning. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 44 REFERENCES
Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant.
  • L. Feinstein, B. Sandmaier, +12 authors R. Storb
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2003
TLDR
Although the length of follow-up is still short, it appears that encouraging outcomes can be achieved with nonmyeloablative conditioning in patients expected to have poor outcomes with conventional allografting. Expand
Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
  • F. Baron, M. Maris, +9 authors R. Storb
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
New approaches aimed at reducing the incidence of grade 2 to 4 acute GVHD might improve survival after allogeneic HCT after nonmyeloablative conditioning. Expand
Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.
TLDR
Despite being evaluated in elderly patients with MM, this 2-step approach has reduced the acute toxicities of allogeneic HCT while achieving potent antitumor activities. Expand
Role of nonmyeloablative allogeneic stem-cell transplantation after failure of autologous transplantation in patients with lymphoproliferative malignancies.
TLDR
The low incidence of early GVHD enabled the subsequent administration of DLI to improve further clinical responses in this poor-risk group of lymphoma and myeloma patients and is a relatively safe option compared with conventional allogeneic transplantation for patients who have failed previous autologous SCT. Expand
HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia.
  • F. Baron, M. Maris, +10 authors R. Storb
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2005
We evaluated 10/10 HLA antigen-matched unrelated hematopoietic cell transplantation (HCT) after nonmyeloablative conditioning with fludarabine 3 x 30 mg/m2 and 2 Gy of total body irradiation asExpand
Extending Postgrafting Cyclosporine Decreases the Risk of Severe Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation
TLDR
Longer CSP duration decreased the risk of severe GVHD and increased the likelihood of discontinuing all systemic immunosuppression after nonmyeloablative HCT with HLA-matched related grafts. Expand
Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.
TLDR
DLI is a potential treatment strategy, with acceptable toxicity, for patients with persistent, relapsed, or progressive disease after nonmyeloablative hematopoietic cell transplantation, retrospectively analyzed data. Expand
Second allogeneic stem cell transplantation using nonmyeloablative conditioning for patients who relapsed or developed secondary malignancies following autologous transplantation.
TLDR
The results suggest that nonmyeloablative conditioning significantly reduces transplant-related toxicity, thus making a second transplant feasible. Expand
Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
  • B. Dey, S. McAfee, +8 authors T. Spitzer
  • Medicine
  • Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2001
TLDR
This novel nonmyeloablative alloSCT strategy followed by prophylactic DLI was well tolerated and can result in durable disease-free survival among patients with advanced hematologic malignancies after a failed autoSCT. Expand
Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
TLDR
Measuring the levels of peripheral blood cell subset donor chimerisms provided useful information on HCT outcomes and might allow early therapeutic interventions to prevent graft rejection or disease progression. Expand
...
1
2
3
4
5
...